Prasad Sunkara, Ph. D Email and Phone Number
Prasad Sunkara, Ph. D work email
- Valid
- Valid
- Valid
Prasad Sunkara, Ph. D personal email
- Valid
Prasad Sunkara, Ph. D phone numbers
Dr. Sunkara is a seasoned CEO, accomplished scientist, serial entrepreneur and a successful investor. He helped in building several startup Life Science companies, hiring great talent leading to successful exits.He combines over 35 years of corporate, financing, research, development and management experience in cancer, cardiovascular, CNS disease indications, molecular diagnostics and devices at Marion Merrell Dow pharmaceuticals (now Sanofi Aventis) and twelve other start up biotech and Medical Device companies in California and Michigan. Dr. Sunkara is an expert in identifying and licensing compelling technologies from universities and accelerating their preclinical and clinical development on a virtual basis while minimizing costs. He also gained valuable experience in business development, financing as an officer in four and as a founder, CEO and Board member at nine other start-up biotech, diagnostic and device companies. He helped them to grow and exit with significant appreciation to shareholders. As Senior Managing Director of a Life Science focused investment bank, he also successfully assisted a number of health care companies with strategic advice , fund raising, mergers and acquisitions.Currently he is actively assisting a number of start up Biotech, Medical device and diagnostic companies as Life Sciences Committee member at NuFund Venture Group, active investor, Board member and advisor.He is the founder and Managing Director of Seed to Fruit LLC (STF), a startup studio and accelerator. Eyegenex, Inc., is the first startup established by STF to develop gene and peptide therapeutics for the treatment of glaucoma, a major unmet medical need in ophthalmology.Dr. Sunkara is an author of over 140 peer reviewed publications and an inventor of 35 patents.Specialties: Biotechnology, Medical Devices Diagnostics, CRO and therapeutics start up, management, research and development, financing and business development. Operations, P&L responsibility, Pharmaceutical, medical device and diagnostics virtual development, Cross border development in India and US. Investment, Mergers , Acquisitions and negotiating licensing deals with Biotech and Pharmaceutical companies. Angel investment, private equity and Venture Capital investment.
-
Co Founder And Chief Executive OfficerEyegenex, Inc., (Www.Eyegenex.Com) Mar 2023 - PresentSan Diego CaEyegenex,Inc is developing gene and peptide therapeutics for the treatment of Glaucoma and help in Preventing blindness.
-
Co Founder And ChairmanPeroral Biosciences, Inc. Jul 2023 - PresentSan Diego, California, United States
-
Founder And Managing DirectorSeed To Fruit Ventures Llc Jan 2022 - PresentLa Jolla, California, United StatesSeed to Fruit (STF) is a founding studio and an accelerator for new startups leveraging on University IP, providing early pre-seed funding and accelerating the initial product development under the guidance of exceptional Advisors consisting of physicians, scientists, biomedical engineers and Angel investors.Eyegenex, Inc, is the first portfolio company of the STF. Eyegenex is focusing on developing gene and peptide therapeutics for the treatment of Glaucoma.
-
Co Founder And PartnerSemg Llc- Startup Express Jan 2022 - PresentCalifornia, United StatesStartup Express multi-class LLCs enable accredited investors to expand and diversify their investments in smaller amounts and at a lower cost.
-
Executive ChairmanHai Solutions Feb 2023 - PresentCarlsbad, California, United StatesHAI Solutions is developing a unique portfolio of medical devices that addresses the growing plague of contamination within the Operating Room, Emergency Room, and Intensive Care Units. Our platform of innovative vascular access technology targets the prevention of Healthcare-Associated Infections like CLABSI, CRBSI, and SSI.
-
Executive AdvisorHai Solutions Inc. (Formerly Enspero Medical) Jun 2020 - PresentCarlsbad, California, United States
-
Member, Lifescience Screening CommitteeNufund Venture Group Aug 2017 - PresentSan Diego County, California, United States -
Chairman, Life Sciences CommitteeTech Coast Angels San Diego Mar 2018 - Aug 2022San Diego, California
-
Member, Board Of DirectorsNufund Venture Group (Formerly Tech Coast Angels) Jan 2020 - Dec 2023San Diego, California
-
AdvisorPlantform Corporation Jan 2018 - Dec 2023Toronto, Ontario, Canada -
AdvisorTosk, Inc. Jun 2016 - Dec 2023Sunnyvale, California -
Entrepreneur In ResidenceUc San Diego Office Of Innovation And Commercialization Sep 2019 - Sep 2020San Diego, CaAssisting students and professors in successful formation of startup Life science companies as part of Office of Innovation and Commercialization at University of California at San Diego, CA. -
Board Member( Observer)Paradigm Diagnostics Feb 2019 - Mar 2020Phoenix, ArizonaParadigm was acquired by Exact Sciences on March 3, 2020.
-
Chairman Of The BoardCorvida Medical Inc., Sep 2012 - Sep 2017Iowa City, Iowa AreaRights for distribution of Halo device was acquired by Fresenius Kabi. Medical device Company developing Closed System Transfer Device for compounding cytotoxic anticancer and antiviral drugs.
-
AdvisorTuimed Mar 2016 - Apr 2017Minneapolis, MinnesotaMedical Device company developing breakthrough technologies for surgical resection of prostate in Benign Prostatic Hypertrophy patients.
-
Co-Founder, Board MemberTranslational Medicine India Oct 2004 - Dec 2013TMI focuses on conducting phase 2 proof of concept studies in oncology, gastroenterology and diabetes as per GCP regulations leveraging the talent, access to patient population and cost advantages in India.
-
President, Ceo And Board MemberEverist Genomics, Inc Oct 2010 - Jul 2012Ann Arbor, MiDeveloped strategy to transform the company into a Medical device and diagnostic company with multiple products. Raised needed capital and executed the business plan into obtaining regulatory approvals and consummated marketing deals in India and Middle East.
-
Chairman And Chief Executive OfficerAngiologix Jul 2010 - Jul 2012Ann Arbor, MiIdentified and licensed Angiodefender device. Assited in obtaining the CE mark for the device and merger with Everist Genomics.
-
Senior Managing DirectorNorth Star Capital Advisors Jun 2009 - Jul 2012Advising and managing development of strategy, fund raising and M&A assistance for Medical Device and biotech companies. The company has successfully completed a number of transactions in US, Europe, India and Middle East.
-
Board MemberUltriod And Vascular Technologies, Inc. St.Petersburg, Fl Aug 2009 - Dec 2011Assisted in Strategy, Research and Development as a Board member.
-
Advisor And ConsultantM &A Group, Rodman And Renshaw Inc Aug 2007 - Dec 2008Part of a team that helped in completing acquisition of a US biotech company and Licensing of Clinical stage assets by a Swiss Pharma company worth $300 Millions.
-
Chairman, Ceo And Co-FounderMolecular Therapeutics,Inc Sep 2002 - Aug 2007Responsible for the overall administration, operation and strategic planning of this Ann Arbor, MI. based Biotech Company focusing on developing novel imaging and therapeutic agents for cancer and cardiovascular therapeutic areas based on proprietary drug delivery and molecular technology.I helped to transform the company into a holding company of three biotech companies.Two CROs ( Molecular Imaging Research, Inc and Translational Medicine India) and a therapeutic company (MRX… Show more Responsible for the overall administration, operation and strategic planning of this Ann Arbor, MI. based Biotech Company focusing on developing novel imaging and therapeutic agents for cancer and cardiovascular therapeutic areas based on proprietary drug delivery and molecular technology.I helped to transform the company into a holding company of three biotech companies.Two CROs ( Molecular Imaging Research, Inc and Translational Medicine India) and a therapeutic company (MRX Therapeutics,Inc). Both companies were acquired by Charles River labs in 2008 for a significant ROI to shareholders. Show less
-
Chairman, Ceo And Co-FounderMolecular Imaging Research,Inc Aug 2003 - Aug 2006Co founded a CRO with unique capabilities of in vivo efficacy evaluation (in a number of therapeutic areas) combining with molecular imaging modalities such as MRI, CT, PET imaging technologies of pre clinical and clinical compounds. This company was acquired by Charles River Labs in 2008 for a significant ROI for share holders.
-
Founder And CeoCascade Pharmaceuticals,Inc Jan 2001 - Sep 2002Execute the business model as a technology transfer company in licensing products and drug delivery technologies with phase 1 data in therapeutic area of cancer from universities and non-profit institutes. Identified a cancer technology and helped to form Novacea by working with Dr. Eckard Weber, a venture partner with Domain Associates. Responsible to successfully obtain orphan drug approval of Bryostatin-1 and in licensing of the compound to GPC Biotech. Cascade merged with Molecular… Show more Execute the business model as a technology transfer company in licensing products and drug delivery technologies with phase 1 data in therapeutic area of cancer from universities and non-profit institutes. Identified a cancer technology and helped to form Novacea by working with Dr. Eckard Weber, a venture partner with Domain Associates. Responsible to successfully obtain orphan drug approval of Bryostatin-1 and in licensing of the compound to GPC Biotech. Cascade merged with Molecular Therapeutics, Inc, an Ann Arbor, MI. based Biotechnology Company in September1, 2003. Show less
-
Executive Vp, Research And DevelopmentCytovia Aug 1999 - Jan 2001Greater San Diego AreaReporting to the CEO and as an officer of the company, I was responsible for the overall research, preclinical and clinical development of lead caspase inhibitors and inducer compounds discovered by Cytovia’s proprietary screening technology. I was responsible for developing the strategy, budget and execution of both research and development. I was part of the management team that raised about $19 million in VC investment over a period of two years and sold the company to Maxim… Show more Reporting to the CEO and as an officer of the company, I was responsible for the overall research, preclinical and clinical development of lead caspase inhibitors and inducer compounds discovered by Cytovia’s proprietary screening technology. I was responsible for developing the strategy, budget and execution of both research and development. I was part of the management team that raised about $19 million in VC investment over a period of two years and sold the company to Maxim Pharmaceuticals, Inc for $70 million in June 2000 Show less
-
Vp, Drug DevelopmentCytokine Networks,Inc, Jul 1997 - Aug 1999Reporting to the CEO and as an officer of the company, I was responsible for the overall preclinical and clinical development of lead compounds acquired from collaborations with the Picower Institute of Medical Research. I was responsible for virtual development of all the preclinical aspects of drug development (cGMP manufacturing of drug substance and drug product, GLP toxicology and pharmacokinetic studies.I was part of the management team that raised about $7 million in investment over… Show more Reporting to the CEO and as an officer of the company, I was responsible for the overall preclinical and clinical development of lead compounds acquired from collaborations with the Picower Institute of Medical Research. I was responsible for virtual development of all the preclinical aspects of drug development (cGMP manufacturing of drug substance and drug product, GLP toxicology and pharmacokinetic studies.I was part of the management team that raised about $7 million in investment over a period of two years and sold the company to Pharmasciences, Inc for $40 million in July 1999. Show less
-
Director, Product DevelopmentNeurocrine Biosciences Sep 1994 - Jul 1997Reporting to the CEO, I am primarily responsible for preclinical and pharmaceutical development and filing of INDs with both the U.S. FDA and Canadian HPB for the initiation of clinical trials. During the past three years, I have developed expertise in conducting all the preclinical and pharmaceutical development efforts, such as analytical methods development, PK, GLP toxicology, ADME studies, GMP synthesis of drug substance and products by closely working with a number of contract research… Show more Reporting to the CEO, I am primarily responsible for preclinical and pharmaceutical development and filing of INDs with both the U.S. FDA and Canadian HPB for the initiation of clinical trials. During the past three years, I have developed expertise in conducting all the preclinical and pharmaceutical development efforts, such as analytical methods development, PK, GLP toxicology, ADME studies, GMP synthesis of drug substance and products by closely working with a number of contract research organizations in U.S., Canada and the UK. I have filed two pre-IND documents and five IND filings (including one physician-sponsored IND) with the U.S. FDA and Canadian HPB for two products.I also had secondary responsibility of in-licensing compounds from academic institutions and acquiring diverse compound libraries for high throughput screening from around the world with a budget of $ 1million. I directed all the preclinical and product development efforts for the company. The company went public (NBIX) in 1996 at a valuation of $400 million. Show less -
Head, Tumor BiologyMarion Merrell Dow (Sanofi Aventis) May 1980 - Sep 1993Responsible for the discovery and preclinical development of lead compounds in the therapeutic areas of cancer and virology.During my tenure at MMD, I built the tumor biology group from four people to a group of twenty-five scientists and lead the discovery and development team. I published about ninety papers in peer review journals and was an inventor of thirty U.S. and worldwide patents. I was responsible for filing a number of INDs for compounds in virology and cancer therapeutic… Show more Responsible for the discovery and preclinical development of lead compounds in the therapeutic areas of cancer and virology.During my tenure at MMD, I built the tumor biology group from four people to a group of twenty-five scientists and lead the discovery and development team. I published about ninety papers in peer review journals and was an inventor of thirty U.S. and worldwide patents. I was responsible for filing a number of INDs for compounds in virology and cancer therapeutic areas. Show less
-
Assistant Professor Of Cell BilogyMd Anderson Cancer Center Aug 1977 - Aug 1980Conducted original research cell cycle regulation in tumor cells. Published 24 peer reviewed publications in prestigious journals. Awarded two R01 grants. One from NCI with perfect score (100) and the second one from American Cancer Society.
Prasad Sunkara, Ph. D Skills
Prasad Sunkara, Ph. D Education Details
-
The University Of Texas Md Anderson Cancer Center Uthealth Graduate School Of Biomedical SciencesCell And Tumor Biology -
Microbiology And Cell Biology -
Acharya N.G. Ranga Agricultural UniversityFirst Class With Honors
Frequently Asked Questions about Prasad Sunkara, Ph. D
What company does Prasad Sunkara, Ph. D work for?
Prasad Sunkara, Ph. D works for Hai Solutions
What is Prasad Sunkara, Ph. D's role at the current company?
Prasad Sunkara, Ph. D's current role is Managing Director, Seed to Fruit Fund.
What is Prasad Sunkara, Ph. D's email address?
Prasad Sunkara, Ph. D's email address is ps****@****ail.com
What is Prasad Sunkara, Ph. D's direct phone number?
Prasad Sunkara, Ph. D's direct phone number is +173422*****
What schools did Prasad Sunkara, Ph. D attend?
Prasad Sunkara, Ph. D attended The University Of Texas Md Anderson Cancer Center Uthealth Graduate School Of Biomedical Sciences, Indian Institute Of Science (Iisc), G. B. Pant University Of Agriculture & Technology, Acharya N.g. Ranga Agricultural University.
What skills is Prasad Sunkara, Ph. D known for?
Prasad Sunkara, Ph. D has skills like Biotechnology, Pharmaceutical Industry, Drug Discovery, Drug Development, Life Sciences, Clinical Development, Technology Transfer, Lifesciences, Oncology, Medical Devices, Start Ups, Strategy.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial